Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

BEAM

Beam Therapeutics Inc

May 03 • 04:00PM ET

23.13

Dollar change +0.41
Percentage change 1.80	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI VB ARKG IWM VBK VXF FBT IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-1.91	Insider Own	16.88%	Shs Outstand	81.63M	Perf Week	8.19%
Market Cap	1.89B	Forward P/E	-	EPS next Y	-5.06	Insider Trans	-7.32%	Shs Float	67.88M	Perf Month	-20.32%
Income	-132.53M	PEG	-	EPS next Q	-1.42	Inst Own	75.47%	Short Float	19.41%	Perf Quarter	-10.76%
Sales	377.71M	P/S	5.00	EPS this Y	-212.06%	Inst Trans	-0.68%	Short Ratio	8.68	Perf Half Y	9.93%
Book/sh	12.02	P/B	1.92	EPS next Y	5.78%	ROA	-9.46%	Short Interest	13.17M	Perf Year	-26.90%
Cash/sh	14.57	P/C	1.59	EPS next 5Y	-3.70%	ROE	-15.46%	52W Range	16.95 - 49.50	Perf YTD	-15.03%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.58%	ROI	-11.61%	52W High	-53.27%	Beta	1.87
Dividend TTM	-	Quick Ratio	5.89	Sales past 5Y	43297.50%	Gross Margin	92.82%	52W Low	36.46%	ATR (14)	1.53
Dividend Ex-Date	Feb 04, 2014	Current Ratio	5.89	EPS Y/Y TTM	54.77%	Oper. Margin	-46.73%	RSI (14)	36.73	Volatility	6.01% 5.20%
Employees	436	Debt/Eq	0.18	Sales Y/Y TTM	520.01%	Profit Margin	-35.09%	Recom	1.93	Target Price	49.54
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	418.68%	Payout	-	Rel Volume	0.69	Prev Close	22.72
Sales Surprise	1593.33%	EPS Surprise	350.29%	Sales Q/Q	1478.04%	Earnings	Feb 27 BMO	Avg Volume	1.52M	Price	23.13
SMA20	-5.89%	SMA50	-25.88%	SMA200	-14.69%	Trades		Volume	1,047,118	Change	1.80%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight	$38 → $40
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral	$35
Dec-08-23	Downgrade	Jefferies	Buy → Hold	$75 → $30
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform	$75 → $20
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Mar-21-23	Initiated	Bernstein	Mkt Perform	$37
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$62
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$61 → $66
Dec-13-22	Initiated	Citigroup	Buy	$62
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$41
Apr-28-22	Initiated	Credit Suisse	Neutral	$62
Jan-05-22	Initiated	Guggenheim	Buy	$130
Oct-19-21	Initiated	SVB Leerink	Outperform	$117
Sep-24-21	Resumed	Stifel	Buy	$85 → $120
Sep-10-21	Initiated	BofA Securities	Buy	$150
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform	$85
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight	$47 → $90
Feb-16-21	Initiated	Wells Fargo	Overweight	$145
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral	$100

Show Previous Ratings

May-01-24 10:01AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Mar-28-24 11:30AM	Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? (Zacks)
Mar-26-24 06:30AM	Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire)
Feb-28-24 06:30AM	Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences (GlobeNewswire)
Feb-27-24 04:01PM	Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug (Investor's Business Daily) +25.89%
02:57PM	Loading…
02:57PM	Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat (Investor's Business Daily)
12:33PM	Beam Shares Rise As Q4 Results Beat Street (RTT News)
07:11AM	Beam Therapeutics Inc (BEAM) Reports Strong Year-End Financials with Key Clinical Milestones on ... (GuruFocus.com)
06:30AM	Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline (Zacks)
Feb-16-24 02:46PM	Beam Therapeutics Stock Shows Healthy Relative Strength Improvement (Investor's Business Daily)
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-07-24 07:35AM	3 Biotech Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Feb-05-24 06:30AM	Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 06:21PM	Why Beam Therapeutics Stock Zoomed 17% Higher Today (Motley Fool) +16.47%
01:51PM	Loading…
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
09:00AM	3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace)
Jan-08-24 06:30AM	Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones (GlobeNewswire) +6.87%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-02-24 06:30AM	Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 10:30AM	2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street (Motley Fool)
Dec-15-23 10:22AM	11 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Dec-14-23 06:30AM	Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors (GlobeNewswire) +5.34%
Dec-08-23 11:30AM	Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report? (Zacks) -8.17%
Nov-30-23 09:55AM	Wall Street Analysts Believe Beam Therapeutics Inc. (BEAM) Could Rally 81.29%: Here's is How to Trade (Zacks)
Nov-23-23 11:03AM	Beam Therapeutics Inc's Chief Legal Officer Christine Bellon Sells 10,000 Shares (GuruFocus.com)
09:42AM	14 Best Short-Term Stocks to Invest In (Insider Monkey)
Nov-20-23 05:43PM	The 3 Best Gene Editing Stocks on the Frontier of Medicine (InvestorPlace) +11.98%
Nov-18-23 07:15AM	Is Beam Therapeutics Stock a Buy Now? (Motley Fool)
06:49AM	Loading…
06:49AM	3 Monster Stocks in the Making (Motley Fool)
Nov-17-23 12:00PM	What Makes Beam Therapeutics Inc. (BEAM) a New Buy Stock (Zacks) +10.81%
Nov-14-23 05:50AM	Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks (Motley Fool) +11.90%
Nov-10-23 09:55AM	Does Beam Therapeutics Inc. (BEAM) Have the Potential to Rally 139.76% as Wall Street Analysts Expect? (Zacks)
Nov-09-23 01:04PM	Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates (Zacks)
Nov-08-23 06:30AM	Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference (GlobeNewswire) -8.36%
06:30AM	Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-05-23 08:30AM	2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now (Motley Fool)
Nov-01-23 05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +10.62%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
10:01AM	Will CRISPR Therapeutics AG (CRSP) Report Negative Q3 Earnings? What You Should Know (Zacks)
10:00AM	After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy? (Motley Fool)
06:00AM	Beam Announces Agreement for Lilly to Acquire Beam's Opt-In Rights to Verve Therapeutics' Base Editing Programs for Cardiovascular Disease (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
09:18AM	5 Reasons Beam Therapeutics Remains a Risky Stock (Motley Fool)
Oct-27-23 07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
Oct-25-23 06:30AM	Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT (GlobeNewswire)
05:50AM	Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble? (Motley Fool)
01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-21-23 08:45AM	Beam Therapeutics Stock: Bear vs. Bull (Motley Fool)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
09:37AM	SolarEdge downgraded, Crocs upgraded: Wall Street's top analyst calls (The Fly)
Oct-19-23 09:03AM	UPDATE 2-Beam Therapeutics to cut 20% of workforce as part of restructuring plan (Reuters) -11.73%
08:54AM	Beam Therapeutics to cut 20% of workforce (Reuters)
08:45AM	Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline (GlobeNewswire)
Oct-18-23 09:30AM	1 Risky Biotech Stock to Consider Buying, and 1 to Avoid (Motley Fool) -6.60%
Oct-05-23 08:45AM	2 Cathie Wood Stocks I'm Bullish On (Motley Fool)
Oct-03-23 06:27AM	Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? (Motley Fool)
Sep-29-23 10:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Sep-27-23 08:30AM	2 Magnificent Growth Stocks to Buy On the Dip (Motley Fool)
Sep-22-23 05:50AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too (Motley Fool)
Sep-08-23 08:20AM	This Cathie Wood Stock Is Down 40% in 2023. Here's Why She's Still Buying It. (Motley Fool)
07:23AM	Cathie Wood's Buying These 3 Stocks Hand Over Fist (Motley Fool)
Sep-07-23 10:00AM	Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation (GlobeNewswire)
Sep-05-23 06:30AM	Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL (GlobeNewswire)
Aug-31-23 07:37AM	10 Stocks That Could 10X Over the Next 10 Years (Insider Monkey)
06:30AM	Beam Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-26-23 07:50AM	3 Cathie Wood Stocks With Parabolic Growth Potential, According to Wall Street (Motley Fool)
Aug-19-23 05:52AM	Got $200? 3 Growth Stocks to Buy That Could Double Your Money (Motley Fool)
Aug-13-23 09:28AM	With 75% ownership of the shares, Beam Therapeutics Inc. (NASDAQ:BEAM) is heavily dominated by institutional owners (Simply Wall St.)
Aug-11-23 09:35AM	Down -20.85% in 4 Weeks, Here's Why Beam Therapeutics Inc. (BEAM) Looks Ripe for a Turnaround (Zacks)
Aug-08-23 07:40AM	Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-15-23 03:45PM	2 Supercharged Growth Stocks That Could Make You Richer (Motley Fool)
Jul-09-23 10:23AM	Beam Therapeutics (NASDAQ:BEAM shareholders incur further losses as stock declines 4.6% this week, taking one-year losses to 41% (Simply Wall St.)
Jun-18-23 05:52AM	Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy (Motley Fool)
Jun-15-23 08:22AM	Again After a Significant Correction, Beam Therapeutics Looks Interesting Again (TheStreet.com)
08:22AM	After a Significant Correction, Beam Therapeutics Looks Interesting Again (TheStreet.com)
May-21-23 08:23AM	Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You? (Motley Fool)
May-17-23 06:30AM	Beam Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-16-23 05:50AM	Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You? (Motley Fool) -5.92%
May-11-23 06:30AM	Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference (GlobeNewswire)
May-10-23 07:45AM	Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results (GlobeNewswire)
May-02-23 12:25PM	7 Best Cathie Wood Stocks for Your May 2023 Buy List (InvestorPlace)
05:53AM	3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers (Motley Fool)
Apr-28-23 04:51PM	The 3 Most Promising Gene Editing Stocks to Buy in 2023 (InvestorPlace)
Apr-26-23 02:10PM	12 Gene Editing Stocks With the Best Long-Term Potential (Insider Monkey)
Apr-20-23 06:24PM	Top 10 CRISPR Stocks To Buy (Insider Monkey)
Apr-18-23 03:47PM	3 Stocks to Watch in April: Is it Time to Buy? (InvestorPlace)
07:00AM	7 Top Growth Stocks to Buy for the Next Decade (InvestorPlace)
Apr-15-23 08:26AM	Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation (Simply Wall St.)
Mar-29-23 08:54PM	7 Biotech Stocks to Buy for Breakthrough Treatments and Cures (InvestorPlace)
04:20PM	11 Most Promising Gene Editing Stocks According to Analysts (Insider Monkey)
Mar-27-23 07:30AM	Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day (GlobeNewswire)
Mar-21-23 06:30AM	Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer (GlobeNewswire)

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simon Amy	Chief Medical Officer	Apr 02 '24	Sale	30.54	16,530	504,851	70,060	Apr 03 07:43 PM
Evans John M.	CEO	Apr 01 '24	Sale	32.13	18,102	581,617	1,058,343	Apr 03 07:36 PM
Simon Amy	Chief Medical Officer	Apr 01 '24	Sale	32.13	7,157	229,954	86,590	Apr 03 07:43 PM
Burrell Terry-Ann	Chief Financial Officer	Apr 01 '24	Sale	32.12	5,446	174,926	70,137	Apr 03 07:39 PM
Ciaramella Giuseppe	President	Apr 01 '24	Sale	32.12	4,534	145,632	169,616	Apr 03 07:33 PM
Bellon Christine	Chief Legal Officer	Apr 01 '24	Sale	32.12	3,401	109,240	104,594	Apr 03 07:40 PM
Evans John M.	CEO	Mar 28 '24	Sale	33.86	60,000	2,031,402	998,262	Apr 01 04:10 PM
FMR LLC	See Remark 1	Feb 14 '24	Sale	30.55	900,000	27,496,912	1,235,511	Feb 15 02:34 PM
FMR LLC	See Remark 1	Feb 13 '24	Sale	30.76	1,565	48,139	2,771,913	Feb 15 02:34 PM
Evans John M.	CEO	Jan 31 '24	Sale	25.33	60,000	1,519,800	1,058,262	Feb 02 04:05 PM
Bellon Christine	Chief Legal Officer	Jan 03 '24	Sale	26.42	1,907	50,383	80,495	Jan 05 04:30 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Option Exercise	7.22	10,000	72,200	92,402	Nov 22 04:05 PM
Bellon Christine	Chief Legal Officer	Nov 20 '23	Sale	30.50	10,000	305,000	82,402	Nov 22 04:05 PM
Simon Amy	Chief Medical Officer	Oct 30 '23	Sale	18.70	3,448	64,478	65,469	Nov 01 04:30 PM
Ciaramella Giuseppe	President and CSO	Oct 20 '23	Option Exercise	0.67	90,900	60,903	139,150	Oct 24 04:05 PM
Bellon Christine	Chief Legal Officer	Oct 02 '23	Sale	22.85	388	8,866	82,402	Oct 04 04:30 PM
Ciaramella Giuseppe	President and CSO	Jul 24 '23	Option Exercise	7.22	1,206	8,707	49,456	Jul 25 06:36 PM
Ciaramella Giuseppe	President and CSO	Jul 24 '23	Sale	32.01	1,206	38,604	48,250	Jul 25 06:36 PM
Ciaramella Giuseppe	President and CSO	Jul 21 '23	Option Exercise	7.22	91,284	659,070	203,574	Jul 25 06:36 PM
Ciaramella Giuseppe	President and CSO	Jul 21 '23	Sale	32.06	155,324	4,979,687	48,250	Jul 25 06:36 PM
Simon Amy	Chief Medical Officer	Jul 10 '23	Sale	30.48	391	11,918	68,917	Aug 09 04:08 PM

Open in Screener

VERV

Verve Therapeutics Inc

May 03 • 04:00PM ET

6.41

Dollar change +0.26
Percentage change 4.23	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

VERV Verve Therapeutics Inc daily Stock Chart

Held by: VTI VB ARKG ARKK VBK VXF IWM IWN VTWO IBB

Index	RUT	P/E	-	EPS (ttm)	-3.13	Insider Own	30.24%	Shs Outstand	81.97M	Perf Week	4.06%
Market Cap	503.51M	Forward P/E	-	EPS next Y	-3.10	Insider Trans	-0.01%	Shs Float	54.79M	Perf Month	-26.15%
Income	-200.07M	PEG	-	EPS next Q	-0.70	Inst Own	72.69%	Short Float	28.65%	Perf Quarter	-41.78%
Sales	11.76M	P/S	42.82	EPS this Y	8.01%	Inst Trans	24.85%	Short Ratio	11.92	Perf Half Y	-45.45%
Book/sh	7.31	P/B	0.88	EPS next Y	-7.99%	ROA	-27.94%	Short Interest	15.69M	Perf Year	-60.31%
Cash/sh	7.94	P/C	0.81	EPS next 5Y	-	ROE	-34.78%	52W Range	5.84 - 21.42	Perf YTD	-54.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-67.06%	ROI	-30.12%	52W High	-70.07%	Beta	1.94
Dividend TTM	-	Quick Ratio	17.24	Sales past 5Y	126.44%	Gross Margin	10.69%	52W Low	9.76%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	17.24	EPS Y/Y TTM	-7.18%	Oper. Margin	-1897.64%	RSI (14)	29.70	Volatility	8.23% 6.96%
Employees	255	Debt/Eq	0.12	Sales Y/Y TTM	505.77%	Profit Margin	-1701.55%	Recom	1.36	Target Price	31.22
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	-3.83%	Payout	-	Rel Volume	1.06	Prev Close	6.15
Sales Surprise	36.60%	EPS Surprise	8.51%	Sales Q/Q	408.30%	Earnings	Feb 27 BMO	Avg Volume	1.32M	Price	6.41
SMA20	-9.08%	SMA50	-42.14%	SMA200	-50.08%	Trades		Volume	1,394,795	Change	4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-24	Initiated	H.C. Wainwright	Buy	$15
Apr-13-23	Initiated	Canaccord Genuity	Buy	$29
Feb-01-23	Initiated	Cantor Fitzgerald	Neutral	$21
Dec-15-22	Initiated	Goldman	Sell	$13
Oct-06-22	Initiated	Credit Suisse	Neutral	$48
Aug-25-22	Upgrade	Stifel	Hold → Buy	$32 → $56
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$48
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$42
Sep-24-21	Initiated	Stifel	Hold	$58
Jul-12-21	Initiated	William Blair	Outperform	$92
Jul-12-21	Initiated	JP Morgan	Neutral	$50
Jul-12-21	Initiated	Jefferies	Buy	$72
Jul-12-21	Initiated	Guggenheim	Buy	$84

Show Previous Ratings

Today 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-19-24 10:30AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws (PR Newswire)
Apr-06-24 09:50AM	After a Serious Setback, Is Verve Therapeutics a Buy? (Motley Fool)
Apr-03-24 01:40PM	Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls (Zacks)
Apr-02-24 04:04PM	Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily) -34.95%
10:36AM	Loading…
10:36AM	Verve Plunges To Record High After Cholesterol-Lowering Gene Editor Causes Side Effects (Investor's Business Daily)
09:31AM	Verve Falls as Gene-Editing Trial Paused on Safety Issues (Bloomberg)
09:01AM	Verve Plummets To Record Low After Its Gene-Editing Drug Causes Side Effects (Investor's Business Daily)
07:35AM	UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels (Reuters)
07:00AM	Verve Therapeutics Announces Updates on its PCSK9 Program (GlobeNewswire)
03:03AM	Verve pauses base editing trial, shifts strategy after treatment side effect (BioPharma Dive)
Mar-28-24 04:51PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-01-24 04:01PM	Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:02PM	Loading…
Feb-27-24 07:02PM	Verve Therapeutics Inc (VERV) Reports Progress and Financials for Q4 and Full Year 2023 (GuruFocus.com) +21.47%
08:03AM	Verve Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-19-24 04:08PM	3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential (InvestorPlace)
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -9.23%
Feb-12-24 08:30AM	2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare (Motley Fool) +8.31%
Feb-01-24 06:30AM	Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-31-24 12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-17-24 12:04PM	7 Mighty Healthcare Stocks Changing the Game of Medicine (InvestorPlace)
Jan-11-24 04:38PM	3 Stocks to Buy in the Booming Field of Gene Editing (InvestorPlace) -5.66%
Jan-04-24 08:00AM	Analysts Agree These 8 Cathie Wood Stock Picks Will Soar In 2024 (Investor's Business Daily)
Jan-02-24 06:30AM	Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-29-23 12:00PM	Verve Therapeutics (VERV) Moves to Buy: Rationale Behind the Upgrade (Zacks) -6.76%
09:55AM	Wall Street Analysts Think Verve Therapeutics (VERV) Could Surge 217.73%: Read This Before Placing a Bet (Zacks)
Dec-13-23 09:55AM	Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to Trade (Zacks) +9.82%
12:31PM	Loading…
Dec-06-23 12:31PM	Hedge Fund and Insider Trading News: Palliser Capital, Balyasny Asset Management , Millennium Management, Blackwells Capital, Pantera Capital, NCR Voyix Corp (VYX), Verve Therapeutics, Inc. (VERV), and More (Insider Monkey) +7.95%
Dec-01-23 04:00PM	Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement (GlobeNewswire)
Nov-28-23 10:37PM	Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
04:01PM	Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement (GlobeNewswire)
Nov-27-23 09:55AM	Does Verve Therapeutics (VERV) Have the Potential to Rally 260.31% as Wall Street Analysts Expect? (Zacks)
Nov-20-23 04:26PM	Verve Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire) +5.37%
Nov-17-23 03:41PM	Why Verve Therapeutics Stock Crashed as Much as 30% This Week (Motley Fool) +6.83%
Nov-16-23 05:41AM	Verve Therapeutics: Why Great Results Aren't Enough (Motley Fool)
05:20AM	After Its Stock Crashed 42% in 1 Day, Is Verve Therapeutics a Buy? (Motley Fool)
Nov-13-23 07:20PM	Heart Disease Breakthrough by Gene-Editor Verve Knocks Its Stock for a Loop (Barrons.com) -40.83%
04:03PM	Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug (Investor's Business Daily)
02:28PM	Rebel's Edge - November 13: $BA, $VERV, $MNDY, and Harbaugh Stealing Signs (TheStreet.com)
12:17PM	Verve Therapeutics, Immersion fall; Tower Semiconductor, Boeing rise, Monday, 11/13/2023 (Associated Press Finance)
12:07PM	These 2 Stocks Are Making Big Monday Moves (Motley Fool)
08:56AM	Why Is Verve Therapeutics (VERV) Stock Down 39% Today? (InvestorPlace)
Nov-12-23 03:30PM	Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
10:34AM	First look at Verve study data offer base editing proof of principle (BioPharma Dive)
Nov-09-23 09:55AM	Wall Street Analysts Predict a 160.72% Upside in Verve Therapeutics (VERV): Here's What You Should Know (Zacks)
08:00AM	1 Cathie Wood Stock to Buy Hand Over Fist Right Now (Motley Fool)
05:57AM	2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher (Motley Fool)
Nov-07-23 07:56AM	Verve Therapeutics Inc (VERV) Reports Q3 2023 Financial Results (GuruFocus.com) +24.83%
06:36AM	Verve Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-01-23 07:06AM	Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains? (Zacks)
05:40AM	Inside Cathie Woods Portfolio: 3 Stocks She Is Betting Millions On (InvestorPlace)
Oct-31-23 07:09PM	Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today (Motley Fool) +27.95%
04:04PM	Verve Stock Soars On $250 Million Eli Lilly Deal (Investor's Business Daily)
06:01AM	Verve and Lilly Relationship Expands to Include Verve's In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3 (GlobeNewswire)
05:00AM	Lilly buys out Beam in heart drug alliance with Verve (BioPharma Dive)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey) +6.45%
08:30AM	With 1 Roadblock Down, Is Verve Therapeutics a Buy Now? (Motley Fool)
Oct-25-23 01:45AM	These Gene-Editing Stocks Are Survivors. Take Another Look. (Barrons.com)
Oct-23-23 07:38AM	Verve Surges After FDA Lifts Hold on Gene-Editing Therapy (Bloomberg)
06:30AM	Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Oct-10-23 09:45AM	2 Incredible Growth Stocks Near 52-Week Lows to Buy Now (Motley Fool)
Sep-27-23 07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-26-23 06:30AM	Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Associations Scientific Sessions 2023 (GlobeNewswire) +13.75%
Sep-21-23 04:05PM	Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 06:30AM	Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer (GlobeNewswire)
Aug-31-23 10:30AM	1 Cathie Wood Stock That Could Go Parabolic Soon (Motley Fool)
Aug-11-23 09:10AM	Investors in Verve Therapeutics (NASDAQ:VERV) have unfortunately lost 47% over the last year (Simply Wall St.)
Aug-10-23 07:50AM	Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
06:40AM	Verve Therapeutics: Q2 Earnings Snapshot (AP Finance)
06:30AM	Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 06:30AM	Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference (GlobeNewswire)
Jul-25-23 09:55AM	How Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5% (Zacks)
Jul-13-23 09:53AM	Cathie Wood Is Buying This Biotech, but Here's Why I'm Not (Motley Fool)
Jun-16-23 06:02AM	Verve inks gene-editing deal with Lilly worth up to $525M (American City Business Journals)
Jun-15-23 04:07PM	Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million (Investor's Business Daily) +16.02%
06:30AM	Verve Establishes Global Collaboration with Lilly to Advance Verves In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease (GlobeNewswire)
Jun-09-23 08:02AM	12 Best Short Squeeze Stocks to Buy Now (Insider Monkey)
Jun-01-23 06:30AM	Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 06:30AM	Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day (GlobeNewswire)
May-15-23 07:45AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:36AM	Verve Therapeutics: Q1 Earnings Snapshot (AP Finance)
06:30AM	Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-11-23 07:21AM	We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate (Simply Wall St.)
May-09-23 06:30AM	Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference (GlobeNewswire) +9.50%
Apr-20-23 06:24PM	Top 10 CRISPR Stocks To Buy (Insider Monkey)
Mar-31-23 12:04PM	Verve Therapeutics, Inc. (NASDAQ:VERV) insider upped their holding by 2.4% earlier this year (Simply Wall St.)
Mar-27-23 06:30AM	Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day (GlobeNewswire)
Mar-04-23 07:32AM	Verve Therapeutics (NASDAQ:VERV) shareholders are up 4.6% this past week, but still in the red over the last year (Simply Wall St.)
Mar-03-23 06:30AM	Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates (GlobeNewswire)
Mar-02-23 06:30AM	Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +10.83%
Feb-15-23 09:00AM	3 Deeply Undervalued Stocks That Could Double Your Money (Motley Fool)
Feb-14-23 06:30AM	Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia (GlobeNewswire)
Feb-06-23 09:35AM	2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023 (TipRanks)
Feb-01-23 02:10PM	Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics (Benzinga)
Jan-30-23 07:10PM	7 CRISPR Stocks With the Best Long-Term Potential (InvestorPlace)

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nickerson Joan	Chief Administrative Officer	Apr 02 '24	Sale	8.24	1,514	12,475	8,659	Apr 03 05:00 PM
Dorval Allison	Chief Financial Officer	Nov 29 '23	Sale	11.45	554	6,343	4,060	Dec 01 04:30 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BEAM

Beam Therapeutics Inc

VERV

Verve Therapeutics Inc

Upgrade your FINVIZ experience